小野藥品工業：臨床實驗、產品、實績、潛力 是由出版商Espicom Business Intelligence在2011年04月所出版的。
這份英文市場調查報告書包含Pages: 60 價格從美金1040起跳。
2009年對小野藥品工業而言是很嚴苛的一年，過去由於沒有太多競爭者所以在特殊產品方面的販售額穩定上升，但近年來政府為降低價格而實施的各項醫療費用抑制政策，對公司造成了打擊使收益與所得減少，許多企業為了強化市場地位而選擇合併，目前小野藥品工業還沒有合併的意願因此處於十分脆弱的立場。
本報告針對小野藥品工業的企業策略與未來預測進行詳細分析，提供未來七年產品預測、競爭分析、臨床實驗動向，目錄介紹如下。
摘要整理
- 介紹
- 財務實績
- 企業策略
- 產品表現預測
- 臨床實驗分析
- 結論與今後預測
治療分類
R&D臨床實驗
心血管
呼吸器
發炎
中樞神經系統
- 已上市產品
- 研究開發計畫
- ONO-4641
- Remimazolam
- Rivastach
代謝系統
其他
- 已上市產品
- 研究開發計畫
- Asimadoline
- Carfilzomib
- ONO-7643
- ONO-8539
附錄：財務實績
附錄：主要契約
附錄：基礎設施
附錄：主要醫療藥品子公司・合併公司
附錄：產品索引
圖表
Abstract
Report Statistics
|
- Publication Date: April 30th 2011
- Total Number of Pages: 60
- Available Formats: Web, PDF and Paper
|
Snapshot Ono Pharmaceuticals - Is a pharma merger required?
Fiscal 2009 was another difficult period for Ono. Historically, the company
markets products for niche indications, ensuring low competition and steady
sales. However, recent governmental price cuts and the implementation of
various healthcare cost containment policies have hit the company hard,
leading to declines in revenue and income. Ono is not the only Japanese
company to be impacted by these factors, several of its competitors have
entered into mergers to strengthen their position. In recent years, five major
mergers have occurred in Japan to form Dainippon Sumitomo Pharma (Dainippon
and Sumitomo Pharmaceutical), Astellas Pharma (Yamanouchi and Fujisawa),
Mitsubishi-Tanabe Pharma (Mitsubishi Pharma and Tanabe), Daiichi Sankyo
(Daiichi and Sankyo Pharmaceutical) and most recently, Kyowa Hakko Kirin
(Kyowa Hakko and Kirin Brewery). Ono has not announced any merger intentions,
which places the company in a vulnerable position.
If Ono is to emerge from this difficult period, the company will have to
rapidly overhaul its product portfolio to market products with forecasted
long-term growth. To this end, Ono established its Strategic Alliance division
in 2007. This business segment is actively seeking collaborations around the
globe in order to expand the pipeline through licensing agreements and bring
candidate compounds to market more rapidly through research alliances.
Agreements with Merck & Co, Novartis and Astellas have seen the pipeline
bolstered by additions of Glactiv, Rivastach Patch and Recalbon, which are
forecast to make strong contributions to company revenue. Drug development in
Japan is focused on obtaining early approval for late-stage compounds,
leveraged by results from multinational clinical trials and other
international studies. Ono is also focused on acquiring commercialisation
rights to new drug candidates. Gaining new drug approvals in Europe and the
US, particularly in areas of unmet medical need, remains a key focus for Ono.
As one of the smaller players in the Japanese market, and certainly globally,
a portfolio overhaul may not be sufficient to maintain Ono' s centuries old
business. Ono should consider combining its aggressive licensing and
collaborative strategy with a major pharmaceutical merger if it is to return
to sales growth.
Sales of Top Ten Products (2008-2016)
But what' s in the pipeline?
For the full story on Ono Pharmaceutical' s challenges and opportunities order this important strategic analysis today
This new strategic report provides a detailed analysis of Ono Pharmaceutical' s
competitive position and prospect for the futures. Using primary source
information complemented by original 7-year product forecasts and competitive
analysis, the report gives a complete and compelling oversight of the company,
its products, pipeline and prospects.
Buyers of the web edition receive online access for one year via an
easy-to-use interface with fast navigation and a full text search facility.
All formats are the same price.
Report Statistics
- Publication Date: April 30th 2011
- Total Number of Pages: 60
- Available Formats: Web, PDF and Paper
Table of Contents
Latest Results
EXECUTIVE SUMMARY
- Introduction
- Current Financial Position
- Company Performance
- Geographic Segment Performance
- Company Strategy
- R&D Strategy
- Key Agreements
- Employees
- Product Performance Forecasts
- Pipeline Analysis
- Conclusions/Outlook
THERAPEUTIC AREA FOCUS
R&D PIPELINE
CARDIOVASCULAR
- Marketed Products
- R&D Projects
RESPIRATORY
- Marketed Products
- Onon
- R&D Projects
INFLAMMATION
- Marketed Products
- R&D Projects
CNS
- Kinedak
- R&D Projects
- ONO-4641
- Remimazolam
- Rivastach
METABOLISM
- Marketed Products
- R&D Projects
OTHERS
- Marketed Products
- R&D Projects
- ONO-7643
- ONO-8539
APPENDIX 1 - FINANCIAL PERFORMANCE
APPENDIX 3 - KEY AGREEMENTS
- Ansaris
- Array BioPharma Inc
- BioFocus DPI Plc
- BioSeek
- Dainippon Sumitomo Pharma
- Dong-A Pharmaceuticals Co Ltd
- Evotec
- GlaxoSmithKline
- Kyowa Hakko Kirin
- Locus Pharmaceuticals Inc
- Medarex Inc
- Merck & Co
- Nissan Chemical Industries Ltd
- Novartis
- PAION AG
- Progenics Pharmaceuticals
- Recordati
- Sapphire Therapeutics Inc
- Santen Pharmaceutical Co Ltd
- Tioga Pharmaceuticals
- UCB
- Xention
APPENDIX 4 - INFRASTRUCTURE
- Research and Development Facilities
- Manufacturing Facilities
APPENDIX 5 - KEY PHARMACEUTICAL SUBSIDIARIES / JOINT VENTURES
- Subsidiaries
- Joint Ventures
APPENDIX 6 - PRODUCT INDEX
LIST OF TABLES:
- Principal Operating Results
- Recent Product Approvals
- Opalmon/ProRenal Sales by Company (2008-2016)
LIST OF CHARTS:
- Sales by Geographic Area, 2009
- Sales of Top Ten Products (2008-2016)
- Top Selling Products, 2009
- Opalmon/ProRenal Sales (2008-2016)
- Onon Sales (2008-2016)
- Recalbon Sales (2009-2016)
- Glactiv Sales (2009-2016)
- Emend Sales (2009-2017)
- Staybla Sales (2008-2016)
- Carfilzomib Sales (2013-2016)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
